Abstract
A new series of 1,3-oxazole attached to bromonabumetone derivatives have been designed and in silico studying as molecular docking using (GOLD) suite program and determination of pharmacokinetic properties using Swiss ADME suite, and then best fitting compounds were synthesized successfully, and confirmed using spectral analysis FT-IR, 1 HNMR and 13 CNMR. In vitro evaluation as an anti-proliferative activity for epidermal growth factor receptor (EGFR) Tyrosine kinase using MTT assay. The anti-proliferative investigation revealed a dose-dependent impact on lung cancer cells (A549) with inhibitory concentration IC50 for compounds 4b and 4c (6.14 & 14.8) µM, respectively which was significantly higher than that of erlotininb IC50 = 24.6 µM. While compound 4a had IC50 (26.8) µM, which is closely related to erlotininb. Keywords: 1,3-Oxazole, EGFR, nabumetone, A549 cell line, molecular docking, pharmacokinetic study
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
